eClinical Solutions has announced expanded artificial intelligence (AI) and machine learning (ML) capabilities within the elluminate IQ offering. Embedded in elluminate Data Central, the elluminate Clinical Data Cloud’s data management workbench provides access to trial data across systems and sources. elluminate IQ Review (eIQ Review) enables data management teams to utilize these AI/ML capabilities to conduct data review.
The elluminate platform including the expanded eIQ Review capabilities will be featured at industry events across the US and Europe this spring.
eClinical Solutions Expands elluminate IQ Offering for AI-Enabled Data Review to Deliver Increased Efficiencies and Quality to Clinical Data Management. (2023, May 24). Business Wire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.